Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi

Event · Earnings
Original reporting
Published Sep 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AYTU
Neutral
medium confidence
Mentioned
$AYTU
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AYTUNeutralMed
01

Why it matters

The release provides the first public numbers for the EXXUA launch and overall financial health, informing valuation and short‑term trading decisions.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking CNS drug launches and small‑cap earnings beats.

03

What to watch

Cash runway of $26.3 M and upcoming payer negotiations could materially affect future performance.

Relevance 7/10Novelty 8/10Timing: post‑market Sep 22 2026

Background

AYTU BioPharma filed an 8‑K Item 2.02 disclosing its FY2026 and Q4 operational and financial results.

Company-level read

Ticker impact

$AYTUNeutralMedium confidence
Context

SEC 8‑K reports FY2026 and Q4 results with net revenue, adjusted EBITDA and cash balance figures.

Expected impact

Potential modest upside on positive guidance; downside risk if guidance remains weak.

Evidence & confidence

Results are primary disclosure but small scale; market may price in incremental improvement.

Market effects

Highlights growth trajectory for CNS specialty pharma and EXXUA launch within the MDD market.

US‑focused; limited broader regional effect.

Minimal global impact beyond niche CNS sector.

Counterpoint

Revenue decline year‑over‑year and negative adjusted EBITDA suggest the stock may face pressure despite launch momentum.

Key entities

  • Josh Disbrow

    Chief Executive Officer of AYTU providing commentary on results.

Related articles

$AYTUHighAI 9/10

Rosemont to acquire Aytu BioPharma for $2.70 per share

Rosemont Pharmaceuticals will acquire Aytu BioPharma (NASDAQ:AYTU) for $2.70 per share, a 41.1% premium over Aytu's 30-day average. The deal, approved by Aytu's board, is expected to close by late 2026. Aytu focuses on central nervous system disease treatments. Rosemont is backed by private equity firm Inflexion.

$AYTUHigh

Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / Novemb

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.